Navigation Links
New Research Triangle Company Provides Innovative Global Services To The Pharmaceutical Industry
Date:9/26/2013

RALEIGH, N.C., Sept. 26, 2013 /PRNewswire/ -- The Research Triangle is no stranger to the pharmaceutical industry, but newcomer Clintrax Global, Inc. is changing how the industry thinks about clinical trial contract negotiations.

Clintrax Global opened for business in January 2013, with a mission to improve the way clinical trial contracts and budgets are negotiated. The company specializes as a functional service provider for pharmaceutical/biotechnology companies and contract research organizations (CROs) during the process of drug development. Clintrax provides these clients with worldwide contract and budget negotiation services with clinical trial sites including small clinics, large hospitals, and multicenter academic institutions.

Clintrax Global's unique business model is based on a seamless, centrally managed global footprint of in-country legal negotiators, which allows the company to execute agreements in over 60 countries in their local languages, and in accordance with each country's specific legal, regulatory and customary requirements.  The company focuses on shortening negotiation times in order to minimize costly delays in the conduct of clinical trials.  The sooner contracts are negotiated, the sooner the site can begin trial enrollment and provide knowledge about the drug.

Clintrax Global also offers a unique cloud-based tracking and reporting system, which allows clients to monitor and track the contract negotiation process in real time. This transparency gives clients the ability to ascertain the status of any individual contract throughout its life cycle.

Though the company is new, it brings together a team with years of experience, expertise, and success in clinical contracts. "Our personnel's breadth of local legal and budget negotiation experience in clinical trials allows us the flexibility to adapt to each client's needs on a global basis in order to quickly negotiate contracts while maintaining a high level of quality," says Clintrax Global Vice President of Operations, Elizabeth Easley. Clintrax Global endeavors to transform the contract negotiation service model in the clinical trial industry and looks forward to growth as the world's leading functional service provider for clinical trial contract negotiations.

Call Colin Dietch, (919) 322-2398 for more information.


'/>"/>
SOURCE Clintrax Global
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lack of Formulary Access Tops List of Limitations Primary Care Physicians Face With e-Prescribing Systems, Says New Research Report from SciMedica Group MR&C
2. Indivumed Sells Inostics, the plasma-DNA Company, to Sysmex and Expands its Clinical Research Service and Patient Diagnostics Business
3. inVentiv Health Clinical Launches Physician Network For Late-Stage Research
4. Aethlon Medical Announces the Appointment of Dr. Cicek Gercel-Taylor as Clinical Research Director of Exosome Sciences, Inc.
5. MabVax Therapeutics Receives $1,750,000 Small Business Innovation Research Contract Award From The National Cancer Institute To Support Development of Novel Pancreatic Cancer Diagnostic Imaging Agent
6. Research-based Pharmaceutical Industry Calls for Public-Private Sector Engagement to Accelerate Progress Towards the Millennium Development Goals (MDGs) and in Planning New Development Agenda
7. Issuer Ratings, Recognitions, Positive Clinical Results, and Quarterly Dividends - Research Report on Pfizer, UnitedHealth, Merck, Gilead, and Bristol-Myers
8. Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals, and Baxter
9. Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine
10. Successful Clinical Trials, Recognitions, Enrollment in Studies, Product Launches, and Strategic Announcements - Research Report on Boston Scientific, Gilead, Abbott, Actavis, and Covidien
11. New Research Finds Many Seniors Wrongly Think Public Health Insurance Exchanges Are Replacing Medicare Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 ... Review, H1 2016" is a report that provides ... helps strengthen R&D pipelines by identifying new targets ... Company Profiles discussed in this H1 ... Farmaceutiche Riunite Srl, AbbVie Inc., Abiogen Pharma S.p.A., ...
(Date:4/27/2016)... Italy , April 27, 2016 ... linear accelerator (MR-linac) platform will be the focal point ... meeting of the European Society for Radiotherapy & Oncology, ... Elekta,s MR-linac integrates a state-of-the-art radiotherapy system and a ... physician to clearly see the patient,s anatomy in real ...
(Date:4/27/2016)... April 27, 2016 Shire plc (LSE: ... Poulton , Chief Financial Officer, will present at the Deutsche ... MA on Wednesday, May 04, 2016, 10:00 am ... be available on the Presentations and Webcasts section of Shire,s ... the webcast will be available on this same website for ...
Breaking Medicine Technology:
(Date:4/29/2016)... , ... April 29, 2016 , ... ... loans more flexibility in repaying their loans, more information about their loan terms ... when total outstanding student loan debt, including federal and private loans, has reached ...
(Date:4/29/2016)... Petersburg, Fla. (PRWEB) , ... April 29, 2016 ... ... Children’s Hospital surgeon reveals that infants born with severe congenital diaphragmatic hernia have ... babies is born with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails ...
(Date:4/29/2016)... ... April 29, 2016 , ... Mobility Designed is redefining mobility with ... armpits, the M+D Crutch evenly distributes body weight from the elbow to the forearm. ... using the crutches than with other crutches. , Co-founders Max and Liliana Younger were ...
(Date:4/29/2016)... ... , ... Melanoma is the deadliest type of skin cancer. Although only about 1 percent of ... deaths. More than 10,000 people are expected to die of melanoma this year. The risk ... one of the most commonly diagnosed cancers in young women. A recent breakthrough in genetic ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):